Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

Rhea-AI Summary

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) presented new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 SITC Annual Meeting in Boston. The innovative therapy aims to convert immunosuppressive tumor-associated macrophages into immunostimulatory cells, potentially enhancing anti-tumor immunity. Key findings include BDC-3042's ability to selectively activate these macrophages, thereby facilitating anti-tumor activity in preclinical models. Bolt is advancing BDC-3042 through IND-enabling studies as part of its commitment to developing novel cancer immunotherapies.

Positive

• BDC-3042 shows promise in reprogramming tumor-associated macrophages to support anti-tumor immunity.
• Demonstrated minimal binding to peripheral leukocytes, indicating targeted treatment.
• Advancing BDC-3042 through IND-enabling studies, signaling progress in development.

Negative

• None.

REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 Society for Immunotherapy of Cancer (SITC) 37^th Annual Meeting. The conference is being held both virtually and at the Boston Convention and Exhibition Center in Boston, Mass. from Nov. 8-12.

“These new preclinical data highlight the strides we are making in the development of BDC-3042, our Dectin-2-targeting agonistic antibody, as we advance our IND-enabling activities,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. “BDC-3042 has a novel mechanism of action that converts immunosuppressive tumor-associated macrophages into immunostimulatory macrophages, which may be an effective treatment approach across many types of cancer. We look forward to presenting these data to the SITC community and remain dedicated to developing novel treatments for patients with solid tumors.”

Details about the presentation follow, and a copy of the poster will be available on the Publications section of the Bolt Biotherapeutics website at the start of the poster session.

Poster #1348: "BDC-3042: A Dectin-2 agonistic antibody for tumor-associated macrophage-directed immunotherapy.”
Presenter: Justin A. Kenkel, Ph.D.
Details: Friday, Nov. 11, 2022, 9:00 a.m. - 8:30 p.m. EST, Poster Hall

Key Findings from the Study

Tumor-associated macrophages (TAMs) generally support tumor progression by suppressing anti-tumor immune responses. Dectin-2 is expressed by TAMs and agonism of Dectin-2 on TAMs has been shown to drive potent anti-tumor immunity in preclinical animal models. BDC-3042 is an agonistic, Dectin-2-targeted antibody designed to activate TAMs and mediate anti-tumor efficacy, offering a novel approach for macrophage-directed immunotherapy.

• BDC-3042 is designed to reprogram immunosuppressive TAMs into immunostimulatory cells that drive anti-tumor immunity
• BDC-3042 selectively binds to Dectin-2-expressing macrophages and induces an array of pro-inflammatory cytokines, chemokines, and antigen presentation molecules
• BDC-3042 exhibits minimal binding to and activation of peripheral leukocytes
• BDC-3042 repolarizes TAMs toward an immunostimulatory phenotype and mediates anti-tumor activity in tumor-bearing humanized mice

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Bolt Biotherapeutics is currently progressing BDC-1001 through a Phase 1/2 dose-escalation clinical trial, as a monotherapy and in combination with Bristol Myers Squibb’s immune checkpoint inhibitor, Opdivo^® (nivolumab), in a variety of HER2-expressing solid tumors. Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is leveraging its ability to engineer and optimize novel applications of its Boltbody ISACs to develop multiple immuno-oncology candidates through strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.

Opdivo^® is a trademark of Bristol-Myers Squibb Company.

Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

David Schull
Russo Partners, LLC
212-845-4271
david.schull@russopartnersllc.com

FAQ

What is BDC-3042 and its significance in cancer treatment?

BDC-3042 is a Dectin-2 targeting agonistic antibody designed to convert immunosuppressive tumor-associated macrophages into immunostimulatory cells, potentially improving anti-tumor immunity in cancer patients.

When and where was the BDC-3042 data presented?

The preclinical data on BDC-3042 was presented at the 2022 Society for Immunotherapy of Cancer Annual Meeting in Boston from Nov. 8-12, 2022.

What were the key findings presented about BDC-3042?

Key findings included BDC-3042's ability to selectively bind to Dectin-2-expressing macrophages, inducing pro-inflammatory responses, and repolarizing these macrophages to enhance anti-tumor activity in preclinical models.

What is the next step for BDC-3042 following the presentation?

Bolt Biotherapeutics is advancing BDC-3042 through IND-enabling studies, moving closer to clinical trials for further evaluation of its therapeutic potential.

How does BDC-3042 compare to existing cancer therapies?

BDC-3042 utilizes a novel mechanism of action, focusing on reprogramming macrophages rather than directly targeting tumor cells, which may offer a complementary approach to existing immunotherapies.